Fulcrum Therapeutics (FULC) PT Raised to $20 at Stifel

Stifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $20.00 (from $18.00) while maintaining a Buy rating.

The analyst commented, "We reiterate our Buy rating on FULC following 1Q21 update. On the call, management reiterated upcoming data catalysts of late-June (Ph.2b ReDUX4 data in facioscapulohumeral muscular dystrophy [FSHD]) and mid-2021 (Ph.1 healthy volunteer data for FTX-6058). Additionally, the company continues to leverage its proprietary product engine, FulcrumSeek, and plans to advance 2 INDs over the next 24 months. We are updating our model and increasing our TP to $20 (from $18 previously)."

You May Also Be Interested In

• IPG Photonics (IPGP) PT Lowered to $92 at Bernstein SocGen Group
• McDonald's (MCD) PT Raised to $280 at Bernstein SocGen Group
• Piper Sandler Reiterates Neutral Rating on Qualcomm (QCOM)